Mel Mann, World’s Longest Living Gleevec (Imatinib) / TKI Survivor, 31-year terminal Chronic Myeloid Leukemia (CML) Survivor, Clinical Trial Pioneer, and Patient Advocate, shared American Association for Cancer Research (AACR) on X, added:
“Great to see the AACR Center for Cancer Clinical Trials enroll its first patient in AACR-ADOPT-GEA. Personalized strategies that may help patients avoid surgery are an important direction.
Looking forward to the data on response rates and long-term outcomes in this phase II study.”
Quoting AACR:
“We are pleased to announce the first clinical trial sponsored by the new AACR Center for Cancer Clinical Trials:
AACR-ADOPT-GEA. This phase II trial will test whether personalized treatment approaches can help gastroesophageal cancer patients skip surgery.”
Read The Full Statement.
